Fri, Sep 19, 2014, 2:33 PM EDT - U.S. Markets close in 1 hr 27 mins

Recent

% | $
Quotes you view appear here for quick access.

Nordstrom Inc. Message Board

jgmtruth 8073 posts  |  Last Activity: Aug 1, 2014 10:25 AM Member since: Feb 21, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • jgmtruth jgmtruth Aug 1, 2014 10:25 AM Flag

    Not true .Fact is this.Here’s a BushToll nugget that pretty much speaks for itself. When George W. Bush took office on Jan. 20, 2001, the S&P 500 stock market index stood at $1,342.54. The day he left office, it was $805.22, a drop of 40 percent
    The Dow Jones Industrial Average fared a bit better. It dropped only 25 percent. Sadly, the tech-heavy NASDAQ shed 48 percent of its value on President Bush’s watch.Anyone can google it.

    Sentiment: Strong Buy

  • Reply to

    MM play

    by effenberg Jul 31, 2014 9:39 AM
    jgmtruth jgmtruth Jul 31, 2014 10:46 AM Flag

    Market conditions nothing more nothing less .Everything is red.

    Sentiment: Strong Buy

  • Reply to

    the predictable revision of history

    by toast22342000 Jun 13, 2014 8:32 AM
    jgmtruth jgmtruth Jun 13, 2014 3:17 PM Flag

    I agree .Why waste one dime or one american life on Iraq. fool me once shame on you fool me twice shame on me.

    Sentiment: Hold

  • jgmtruth jgmtruth Jun 6, 2014 2:04 PM Flag

    Stop watching FOX news.LOL Same old same old..LOL

  • Republicans are executing some Looney Tunes-style moves as they scramble to condemn the deal releasing Sgt. Bowe Bergdahl, after having earlier called on the Obama administration to work hard to secure his release:
    In the clearest contradiction, Sen. John McCain (R-AZ) told CNN’s Anderson Cooper in February that he “would be inclined to support” “an exchange of prisoners for our American fighting man,” like the one Taliban officials had offered in 2012. He has since labeled Obama’s deal “ill-founded” and a “mistake.” [...]
    Sen. Jim Inhofe (R-OK) — the ranking member of the Senate Armed Services Committee — has also said that the U.S. “must make every effort to bring this captured soldier home to his family.” But appearing on Fox News just days after Bergdahl’s release, Inhofe criticized the administration for agreeing to free “people who have killed Americans, people who are the brain power of Taliban.”

    New Hampshire Sen. Kelly Ayotte ran the same play, focusing repeatedly on the need for Bergdahl's release. Basically, for these charmers, it was "Bring him home, bring him home, why aren't you doing whatever is needed to bring him home? Sure, swap some prisoners, just bring him home" only to be followed by "why did you do that?" once Bergdahl was released. And if President Obama hadn't gone through with the deal and news of that had gone through, McCain would likely have gone charging onto the Sunday morning talk shows to denounce the president for leaving an American soldier in captivity. It's all about opposing Obama with these guys, always.
    Several Republicans also celebrated Bergdahl's release on Twitter, only to delete those tweets as the issue became politicized. Those stalwarts include Reps. Lee Terry and Mark Amodei and Iowa Senate candidate Joni Ernst.

    Sentiment: Buy

  • Reply to

    Years of Living Dangerously

    by toast22342000 May 14, 2014 9:00 AM
    jgmtruth jgmtruth Jun 4, 2014 4:08 PM Flag

    Sen. Marco Rubio (R-FL) is on a roll. For several years he’s flirted with denying that humanity’s use of fossil fuels is the driver behind climate change. But earlier this month Rubio put all his chips on the table: “I don’t agree with the notion that some are putting out there, including scientists, that somehow, there are actions we can take today that would actually have an impact on what’s happening in our climate.”
    Rubio followed that up several days later with a total failure to name a single source for his suggestion that human activity and global warming are unconnected.
    Which brings us to Tuesday, when Rubio dug his hole even deeper on Bill O’Reilly’s show. The Senator claimed in quick succession that there’s no scientific consensus on human responsibility for climate change, that surface temperatures have stabilized over the last two decades, that cutting carbon emissions would destroy the economy, and that U.S. policies won’t do anything about the problem. "Stupid is as stupid does"

    Sentiment: Buy

  • Reply to

    ASCO

    by sschatzi33 May 29, 2014 1:13 PM
    jgmtruth jgmtruth May 29, 2014 4:48 PM Flag

    All different dates .you can go to ASCO 2014 SEARCH Abstracts and search Gilead Sciences .It doesn't get started until tomorrow .

    Sentiment: Strong Buy

  • Reply to

    ASCO

    by sschatzi33 May 29, 2014 1:13 PM
    jgmtruth jgmtruth May 29, 2014 3:53 PM Flag

    ABSTRACT
    Drug interaction profile of idelalisib and its major metabolite, GS-563117.
    Drug interaction profile of idelalisib and its major metabolite, GS-563117. Pharmacology 2593 J Clin Oncol 32:5s, 2014 (suppl; abstr 2593) Feng Jin, Michelle Robeson, Huafeng Zhou, Candra Moyer, Sibylle Wilbert, Bernard Murray, Srini Ramanathan; Gilead Sciences, Foster City, CA; Gilead Sciences ...
    May 29, 2014
    ASSOCIATED CONTENT View Presentation || View Slides
    ABSTRACT
    The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. Pharmacology 2592 J Clin Oncol 32:5s, 2014 (suppl; abstr 2592) Feng Jin, Michelle Robeson, Huafeng Zhou, Grace Hisoire, Srini Ramanathan; Gilead Sciences, Foster City, CA; Gilead Sciences, Seattle, WA ...
    May 29, 2014
    ASSOCIATED CONTENT View Presentation || View Slides
    ABSTRACT
    A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
    Milano, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Gilead Sciences, Inc., Foster City, CA; Gilead Sciences, Foster City, CA; University of Cologne, Cologne, Germany; The Leeds Teaching ...
    May 29, 2014
    ASSOCIATED CONTENT View Presentation || View Slides
    ABSTRACT
    A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.
    MD; Gabrail Cancer Center, Canton, OH; Montgomery Cancer Center, Mt. Sterling, KY; Gilead Sciences ...
    May 29, 2014
    ABSTRACT
    Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
    Germany; Gilead Sciences, Foster City, CA Background: Idelalisib (IDELA) is a potent and selective ...
    May 29, 2014
    ASSOCIATED CONTENT View Presentation || View Slides
    ABSTRACT
    Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.
    of Liverpool, Liverpool, United Kingdom; Gilead Sciences, Foster City, CA; Feinberg School of Medicine, ...
    May 29, 2014
    ASSOCIATED CONTENT View Presentation || View Slides
    ABSTRACT
    Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
    CA; Ventura Oncology, Ventura, CA; Gilead Sciences, Foster City, CA; Gilead Sciences, Branford, CT; ... Hematology/Oncology Associates, Charleston, SC; Oregon Health & Science University, Portland, OR; Georgetown ...
    May 29, 2014
    ASSOCIATED CONTENT View Presentation || View Slides
    ABSTRACT
    Phase 2 trial of GS-9973, a selective Syk inhibitor, in chronic lymphocytic leukemia (CLL).
    Oncology Associates, Tucson, AZ; Compass Oncology, Vancouver, WA; Gilead Sciences, Foster City, CA; Gilead Sciences, Branford, CT; Compass Oncology, , Tualatin, OR Background: Spleen tyrosine kinase (Syk) ...
    May 29, 2014
    ASSOCIATED CONTENT View Presentation || View Slides
    ABSTRACT
    Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.
    of Liverpool, Liverpool, United Kingdom; Gilead Sciences, Foster City, CA; The University of Texas MD Anderson ...
    May 29, 2014
    ASSOCIATED CONTENT View Presentation || View Slides
    ABSTRACT
    A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
    Gilead Sciences, Foster City, CA; Lyon Sud University Hospital, Pierre-Bénite, France Background: PI3Kδ ...
    May 29, 2014
    ASSOCIATED CONTENT View Presentation || View SlidesABSTRACT
    A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
    of Medicine, New York, NY; Virginia K. Crosson Cancer Center, Fullerton, CA; Gilead Sciences, Foster City, CA; ...
    May 29, 2014
    ABSTRACT
    Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).
    Northwestern University, Chicago, IL; Gilead Sciences, Foster City, CA; Lyon Sud University Hospital, ...
    May 29, 2014
    Pages

    Sentiment: Strong Buy

  • May 28, 2014 11:57 a.m. ET
    Credit Suisse

    Heading into the American Society of Clinical Oncology meeting and the second half of 2014, we see recent weakness providing a compelling risk-reward for Outperform-rated Bristol-Myers Squibb.

    Coming out of ASCO, we think Bristol-Myers (ticker: BMY ) could rise by about 10% on better appreciation of the broad potential of these agents following data presentation in the new tumor types, success in the adjuvant setting in melanoma, and development updates in the lung-cancer space. We see limited downside following recent weakness.

    The ASCO meeting will provide investors an opportunity to better appreciate the potential for immuno-oncology (I-O) outside of the lead indications of advanced lung, skin and kidney cancer where attention has been focused for the past couple years. Appreciation for the positive data in tumors such as head and neck, bladder, ovarian, and in the adjuvant setting in melanoma, could conservatively add over $3 billion to the I-O market potential (currently about $13 billion).

    Also, development updates from each of the four main major pharma players in this space (Bristol-Myers, Merck ( MRK ), Roche Holding [of Switzerland] and AstraZeneca ( AZN )) should further help people to realize that the I-O pie is significantly larger than the Street currently appreciates. We believe I-O estimates for all four of these companies could rise in the coming months but continue to see Bristol-Myers as best positioned given the breadth and depth of their clinical development program and how leveraged the company is to I-O.

    Positive news in multiple new indications represent over $3 billion in value to the class and reaffirm our strong belief that I-O could reasonably be in the over $30 billion category. Positive updates in ovarian, bladder, head and neck, Hodgkin's lymphoma and adjuvant melanoma setting largely went unnoticed as the Street remains focused on a handful of datasets in the lead indications of lung, skin and kidney cancer. Our bottoms-up patient opportunity build-up suggests these new indications could conservatively add over $3 billion to the I-O category, benefiting multiple players in the space, and particularly Bristol-Myers who was the source of the positive news or who has active development ongoing in each of the new indications and settings.

    We still see Bristol-Myers best positioned to win given breadth and depth of their clinical development program. Disappointing data-to-date from the nivo-yervoy combination in first line non-small cell lung cancer (NSCLC) is certainly a short-term disappointment, however, the Street is underappreciating the number of options available to Bristol-Myers to continue broad development in this space including use of I-O and chemo combination, yervoy and nivo in PD-L1 (molecule) patients, and other I-O/I-O combinations that Bristol-Myers is testing. Bristol-Myers still has the strongest clinical pipeline in I-O, the broadest clinical-development program and a number of important catalysts at ASCO and beyond that may deliver about 10% upside in the near term and possibly about 20%-30% upside in the next 12-18 months. At ASCO, in addition to data in the new tumor types, we specifically look for important data readouts and updates in adjuvant melanoma, nivo-yervoy in first line NSCLC and nivo-chemo in first-line NSCLC.

    Sentiment: Buy

  • Gilead's blockbuster drug Sovaldi has become a lightning rod in the debate over rising specialty drug prices. The one thing is indisputable, for patients the drug works remarkably well.

    Four weeks into treatment with Sovaldi, 55-year old Michelle Carver of New York said she feels better than she has in years.

    "I'd stopped doing everything because I thought, my liver was failing," she said. Like so many with the virus, she had felt constant fatigue. "Now, I feel so much better. I'm in the gym. I'm eating."

    Carver said she doesn't know how she acquired hepatitis C, which is most common in the U.S. among baby boomers exposed before testing for the virus was developed in the early 1990s. Her best guess is that she might have been exposed from a blood transfusion during an operation, or when she got a tattoo, years ago. I was in shock, when I found out I had it. And I'm in shock to find out that it actually can leave my body," she said.

    Read MoreThe $84,000 question: Will focusing on drug prices rein in costs?

    She said her course of treatment couldn't be easier. She takes just two pills a day at breakfast: Sovaldi, and the companion medication Olysio, made by Johnson & Johnson.
    "It's like taking vitamins every day," she said. "I haven't had one side effect."
    Four weeks into the treatment, Carver was testing negative for the hep C virus, which accounts for one of the leading causes of cirrhosis and liver cancer.

    A breakthrough treatment

    "We're talking about curing people with 98 percent success rate," said Dr. Ari Bunim, a hepatologist at New York Hospital Queens. "It's a whole new ball game."

    Sentiment: Strong Buy

  • jgmtruth jgmtruth May 21, 2014 10:00 AM Flag

    GILD seems to be in fire, just strangely market does not seem to believe potential, HepaC cure, HIV stopper and even upcoming flu medicine are all quite a huge potential money makers. a cure for the common cold.
    Another great leap for a great company.

    Sentiment: Strong Buy

  • jgmtruth jgmtruth May 19, 2014 9:47 AM Flag

    Pharmacyclics Inc. Analyst Notes
    On May 14, 2014, Pharmacyclics Inc. (Pharmacyclics) announced that IMBRUVICA® (ibrutinib) will be highlighted in ten abstracts, including both company-sponsored research studies and investigator-sponsored studies. Pharmacyclics informed that the preliminary data from these abstracts about IMBRUVICA is currently accessible on the website of the American Society of Clinical Oncology (ASCO). However, the updated results will be presented at the 50th Annual Meeting of ASCO being held from May 30, 2014 through June 3, 2014, in Chicago, Illinois. Bob Duggan, CEO and Chairman of the Board, Pharmacyclics, commented, "Presentations at ASCO showcase IMBRUVICA's long-term efficacy and safety profile as a single agent, even in high-risk patients, as well as high response rates with long-term durability when IMBRUVICA is administered in combination with an antibody targeting CD20."

    Sentiment: Strong Buy

  • jgmtruth jgmtruth May 18, 2014 11:26 AM Flag

    Under this link.[PDF] Applications for new human medicines under evaluation April ...
    ... Holoclar Chiesi Farmaceutici SpA Ophthalmologicals Ibrutinib Imbruvica
    Janssen-Cilag International NV Antineoplastic medicines ...

  • jgmtruth jgmtruth May 18, 2014 11:24 AM Flag

    Could be.Committee for Medicinal Products for Human Use (CHMP): 19-22 May 2014.Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use April 2014
    This document lists information on applications for centralised marketing authorisation for human medicines that the European Medicines Agency has received for evaluation. It includes the international non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP). For generic and biosimilar medicines, it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area.
    This list only includes information for medicines whose applications have been validated at the time the report was compiled. The information in this report was compiled on 14 April 2014.
    Information on designated orphan medicines that are being assessed for marketing authorisation is also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).
    Information in bold corresponds to new entries in the monthly list.
    Entries are removed from this list once the medicine has received a positive or negative opinion from the CHMP or when the applicant has withdrawn the application. The Agency publishes information on these opinions and withdrawn applications on its website.
    Information on CHMP opinions is also published in the monthly CHMP highlights.Orphan medicinal products On the list:Ibrutinib Imbruvica Janssen-Cilag International NV

    Sentiment: Strong Buy

  • jgmtruth by jgmtruth May 15, 2014 12:46 PM Flag

    No panic selling here..STRONG BUY

    Sentiment: Strong Buy

  • Baird analyst Brian Skorney reiterated an Outperform rating and $173 price target on Pharmacyclics (NASDAQ: PCYC) saying the ASCO abstracts firms up IImbruvica's competitive profile.

    Skorney comments, "We believe concerns over the competitive landscape in CLL will be kept in check following last night's ASCO abstract release as we believe competitive regimens looked disappointing compared to ibrutinib. ABT-199, in particular, seems to have a high rate of on-treatment progressions, despite what are characterized as deeper initial responses. We believe further data comparisons at ASCO will clearly favor ibrutinib."

    Sentiment: Strong Buy

  • Reply to

    Read this from BRIAN KOFFMAN.

    by jgmtruth May 15, 2014 11:07 AM
    jgmtruth jgmtruth May 15, 2014 12:16 PM Flag

    Thanx but that s not me it's Brian Koffman MD blog.LEARNING FROM AND ABOUT CANCER (CHRONIC LYMPHOCYTIC LEUKEMIA OR CLL) BY BRIAN KOFFMAN.

    Sentiment: Strong Buy

  • jgmtruth by jgmtruth May 15, 2014 11:22 AM Flag

    Imbruvica Updated results will be presented at the 50th Annual Meeting of ASCO being held May 30-June 3, 2014, in Chicago, IL.Dont forget that the data for DLBCL rx with RCHOP +/- Ibru is not disclosed . I am anticipating great news will follow.IMO

    Sentiment: Strong Buy

  • Reply to

    Read this from BRIAN KOFFMAN.

    by jgmtruth May 15, 2014 11:07 AM
    jgmtruth jgmtruth May 15, 2014 11:12 AM Flag

    My latest bone marrow biopsy was 15 months ago in Feb. 2013 and even back then it showed only 4% CLL by flow cytometry down from between 10%-20% a year earlier.

    I am clearly in a very deep and deepening remission.

    I am very grateful.

    On a community note, ibrutinib, the first in class signal blocker (BTK) for CLL, received breakthrough approval in the USA for anyone who has tried at least one prior therapy based on its outstanding safety and efficacy data in all patient groups, including those with 17p deletions and other hard to treat clones. But it is broadly available to any of us who have tried but not necessarily failed just one prior therapy.

  • WEDNESDAY, MAY 7, 2014

    Celebrating My Two Year Anniversary Today on Ibrutinib for My CLL (chronic lymphocytic leukemia)
    Much has happened in the last two years, most of it very good.

    On a personal note, I swallowed my first 3 battleship grey capsules of PCI-32765 (it wasn't even called ibrutinib yet) on May 7, 2012 in a Phase I/II clinical trial at OSU with Dr. Byrd.

    Two years later my lymph nodes have shrunk to less than 1/2 their size with the possibility that all that remains on the CT scans is the scarred shells of what used to be cancerous nodes.

    Today, to find any CLL in my blood, you can no longer rely on the standard bloods test but must do the vey sensitive flow cytometry to find the

    Sentiment: Strong Buy

JWN
69.43+0.16(+0.23%)2:33 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.